B-intervention	0	3	Soy
I-intervention	4	14	isoflavone
O	15	30	supplementation
O	31	34	for
O	35	41	breast
O	42	48	cancer
O	49	53	risk
O	54	63	reduction
O	63	64	:
O	65	66	a
O	67	77	randomized
O	78	83	phase
O	84	86	II
O	87	92	trial
O	92	93	.

O	94	97	Soy
O	98	108	isoflavone
O	109	120	consumption
O	121	124	may
O	125	132	protect
O	133	140	against
O	141	147	breast
O	148	154	cancer
O	155	166	development
O	166	167	.

O	168	170	We
O	171	180	conducted
O	181	182	a
O	183	188	phase
O	189	192	IIB
O	193	198	trial
O	199	201	of
O	202	205	soy
O	206	216	isoflavone
O	217	232	supplementation
O	233	235	to
O	236	243	examine
O	244	247	its
O	248	254	effect
O	255	257	on
O	258	264	breast
O	265	275	epithelial
O	276	289	proliferation
O	290	293	and
O	294	299	other
O	300	310	biomarkers
O	311	313	in
O	314	317	the
O	318	325	healthy
O	326	330	high
O	330	331	-
O	331	335	risk
O	336	342	breast
O	342	343	.

B-total-participants	344	347	One
I-total-participants	348	355	hundred
I-total-participants	356	359	and
I-total-participants	360	366	twenty
I-total-participants	366	367	-
I-total-participants	367	370	six
O	371	380	consented
O	381	386	women
O	387	396	underwent
O	397	398	a
O	399	405	random
O	406	410	fine
O	410	411	-
O	411	417	needle
O	418	428	aspiration
O	429	430	(
O	430	434	rFNA
O	434	435	)
O	435	436	;
O	437	442	those
O	443	447	with
O	448	449	4
O	449	450	,
O	450	453	000
O	454	456	or
O	457	461	more
O	462	472	epithelial
O	473	478	cells
O	479	483	were
O	484	494	randomized
O	495	497	to
O	498	499	a
O	500	506	double
O	506	507	-
O	507	512	blind
O	513	514	6
O	514	515	-
O	515	520	month
O	521	533	intervention
O	534	536	of
O	537	542	mixed
O	543	546	soy
O	547	558	isoflavones
O	559	560	(
O	560	564	PTIG
O	564	565	-
O	565	569	2535
O	569	570	)
O	571	573	or
B-control	574	581	placebo
O	581	582	,
O	583	591	followed
O	592	594	by
O	595	601	repeat
O	602	606	rFNA
O	606	607	.

O	608	613	Cells
O	614	618	were
O	619	627	examined
O	628	631	for
O	632	634	Ki
O	634	635	-
O	635	637	67
O	638	646	labeling
O	647	652	index
O	653	656	and
O	657	663	atypia
O	663	664	.

O	665	675	Expression
O	676	678	of
O	679	681	28
O	682	687	genes
O	688	695	related
O	696	698	to
O	699	712	proliferation
O	712	713	,
O	714	723	apoptosis
O	723	724	,
O	725	728	and
O	729	739	estrogenic
O	740	746	effect
O	747	750	was
O	751	759	measured
O	760	765	using
O	766	778	quantitative
O	779	786	reverse
O	787	800	transcriptase
O	801	804	PCR
O	804	805	.

O	806	813	Hormone
O	814	817	and
O	818	825	protein
O	826	832	levels
O	833	837	were
O	838	846	measured
O	847	849	in
O	850	856	nipple
O	857	865	aspirate
O	866	871	fluid
O	872	873	(
O	873	876	NAF
O	876	877	)
O	877	878	.

O	879	882	All
O	883	894	statistical
O	895	900	tests
O	901	905	were
O	906	909	two
O	909	910	-
O	910	915	sided
O	915	916	.

B-total-participants	917	923	Ninety
I-total-participants	923	924	-
I-total-participants	924	929	eight
O	930	935	women
O	936	940	were
O	941	950	evaluable
O	951	954	for
O	955	957	Ki
O	957	958	-
O	958	960	67
O	961	969	labeling
O	970	975	index
O	975	976	.

O	977	979	In
B-intervention-participants	980	982	49
O	983	990	treated
O	991	996	women
O	996	997	,
O	998	1001	the
B-outcome	1002	1008	median
I-outcome	1009	1011	Ki
I-outcome	1011	1012	-
I-outcome	1012	1014	67
I-outcome	1015	1023	labeling
I-outcome	1024	1029	index
O	1030	1033	was
B-iv-cont-median	1034	1035	1
I-iv-cont-median	1035	1036	.
I-iv-cont-median	1036	1038	18
O	1039	1041	at
O	1042	1047	entry
O	1048	1051	and
B-iv-cont-median	1052	1053	1
I-iv-cont-median	1053	1054	.
I-iv-cont-median	1054	1056	12
O	1057	1061	post
O	1062	1074	intervention
O	1074	1075	,
O	1076	1083	whereas
O	1084	1086	in
B-control-participants	1087	1089	49
O	1090	1097	placebo
O	1098	1106	subjects
O	1106	1107	,
O	1108	1110	it
O	1111	1114	was
B-cv-cont-median	1115	1116	0
I-cv-cont-median	1116	1117	.
I-cv-cont-median	1117	1119	97
O	1120	1123	and
B-cv-cont-median	1124	1125	0
I-cv-cont-median	1125	1126	.
I-cv-cont-median	1126	1128	92
O	1129	1130	(
O	1130	1131	P
O	1132	1135	for
O	1136	1143	between
O	1143	1144	-
O	1144	1149	group
O	1150	1156	change
O	1156	1157	:
O	1158	1159	0
O	1159	1160	.
O	1160	1162	32
O	1162	1163	)
O	1163	1164	.

B-outcome	1165	1175	Menopausal
I-outcome	1176	1190	stratification
O	1191	1198	yielded
O	1199	1206	similar
O	1207	1214	results
O	1215	1222	between
O	1223	1229	groups
O	1229	1230	,
O	1231	1234	but
O	1235	1241	within
O	1242	1255	premenopausal
O	1256	1259	soy
O	1259	1260	-
O	1260	1267	treated
O	1268	1273	women
O	1273	1274	,
B-outcome	1275	1277	Ki
I-outcome	1277	1278	-
I-outcome	1278	1280	67
I-outcome	1281	1289	labeling
I-outcome	1290	1295	index
O	1296	1305	increased
O	1306	1310	from
O	1311	1312	1
O	1312	1313	.
O	1313	1315	71
O	1316	1318	to
O	1319	1320	2
O	1320	1321	.
O	1321	1323	18
O	1324	1325	(
O	1325	1326	P
O	1327	1328	=
O	1329	1330	0
O	1330	1331	.
O	1331	1333	04
O	1333	1334	)
O	1334	1335	.

O	1336	1338	We
O	1339	1342	saw
O	1343	1345	no
O	1346	1355	treatment
O	1356	1362	effect
O	1363	1365	on
B-outcome	1366	1375	cytologic
I-outcome	1376	1382	atypia
I-outcome	1383	1385	or
I-outcome	1386	1389	NAF
I-outcome	1390	1400	parameters
O	1400	1401	.

O	1402	1407	There
O	1408	1412	were
O	1413	1424	significant
O	1425	1434	increases
O	1435	1437	in
O	1438	1441	the
B-outcome	1442	1452	expression
I-outcome	1453	1455	of
I-outcome	1456	1458	14
I-outcome	1459	1461	of
I-outcome	1462	1464	28
I-outcome	1465	1470	genes
O	1471	1477	within
O	1478	1481	the
O	1482	1485	soy
O	1485	1486	,
O	1487	1490	but
O	1491	1494	not
O	1495	1498	the
O	1499	1506	control
O	1507	1512	group
O	1512	1513	,
O	1514	1521	without
O	1522	1533	significant
O	1534	1541	between
O	1541	1542	-
O	1542	1547	group
O	1548	1559	differences
O	1559	1560	.

B-outcome	1561	1567	Plasma
I-outcome	1568	1577	genistein
I-outcome	1578	1584	values
O	1585	1591	showed
O	1592	1601	excellent
O	1602	1612	compliance
O	1612	1613	.

O	1614	1615	A
O	1616	1617	6
O	1617	1618	-
O	1618	1623	month
O	1624	1636	intervention
O	1637	1639	of
O	1640	1645	mixed
O	1646	1649	soy
O	1650	1661	isoflavones
O	1662	1664	in
O	1665	1672	healthy
O	1672	1673	,
O	1674	1678	high
O	1678	1679	-
O	1679	1683	risk
O	1684	1689	adult
O	1690	1697	Western
O	1698	1703	women
O	1704	1707	did
O	1708	1711	not
O	1712	1718	reduce
O	1719	1725	breast
O	1726	1736	epithelial
O	1737	1750	proliferation
O	1750	1751	,
O	1752	1762	suggesting
O	1763	1764	a
O	1765	1769	lack
O	1770	1772	of
O	1773	1781	efficacy
O	1782	1785	for
O	1786	1792	breast
O	1793	1799	cancer
O	1800	1810	prevention
O	1811	1814	and
O	1815	1816	a
O	1817	1825	possible
O	1826	1833	adverse
O	1834	1840	effect
O	1841	1843	in
O	1844	1857	premenopausal
O	1858	1863	women
O	1863	1864	.
